BlackRock Group LTD boosted its stake in Omnicell, Inc. (NASDAQ:OMCL) by 8.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 63,472 shares of the company’s stock after buying an additional 4,726 shares during the period. BlackRock Group LTD owned approximately 0.17% of Omnicell worth $2,431,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the company. Texas Permanent School Fund boosted its position in Omnicell by 0.3% in the third quarter. Texas Permanent School Fund now owns 27,548 shares of the company’s stock valued at $1,055,000 after buying an additional 84 shares during the last quarter. Louisiana State Employees Retirement System boosted its position in shares of Omnicell by 0.6% in the third quarter. Louisiana State Employees Retirement System now owns 16,000 shares of the company’s stock worth $613,000 after buying an additional 100 shares in the last quarter. Eqis Capital Management Inc. boosted its position in shares of Omnicell by 1.9% in the third quarter. Eqis Capital Management Inc. now owns 9,339 shares of the company’s stock worth $358,000 after buying an additional 176 shares in the last quarter. PineBridge Investments L.P. boosted its position in shares of Omnicell by 4.0% in the second quarter. PineBridge Investments L.P. now owns 4,555 shares of the company’s stock worth $156,000 after buying an additional 177 shares in the last quarter. Finally, Arizona State Retirement System boosted its position in shares of Omnicell by 1.6% in the second quarter. Arizona State Retirement System now owns 18,684 shares of the company’s stock worth $640,000 after buying an additional 300 shares in the last quarter. 92.84% of the stock is owned by institutional investors and hedge funds.
Omnicell, Inc. (NASDAQ:OMCL) traded up 0.42% on Friday, reaching $35.75. 178,994 shares of the company traded hands. Omnicell, Inc. has a one year low of $25.06 and a one year high of $40.50. The firm has a 50 day moving average of $33.79 and a 200-day moving average of $35.58. The stock has a market capitalization of $1.31 billion, a PE ratio of 163.99 and a beta of 0.69.
Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, October 27th. The company reported $0.40 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.41 by $0.01. The business had revenue of $179.40 million for the quarter, compared to analyst estimates of $179.75 million. Omnicell had a return on equity of 10.74% and a net margin of 1.24%. The firm’s revenue was up 43.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.36 EPS. On average, analysts anticipate that Omnicell, Inc. will post $1.55 EPS for the current year.
A number of brokerages recently issued reports on OMCL. Oppenheimer Holdings, Inc. set a $46.00 target price on shares of Omnicell and gave the stock a “buy” rating in a research report on Thursday, October 27th. Cantor Fitzgerald began coverage on shares of Omnicell in a report on Thursday, January 5th. They set an “overweight” rating and a $40.00 price objective on the stock. Benchmark Co. increased their price objective on shares of Omnicell from $39.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, December 6th. Dougherty & Co began coverage on shares of Omnicell in a report on Thursday, January 19th. They set a “buy” rating and a $44.00 price objective on the stock. Finally, TheStreet lowered shares of Omnicell from a “buy” rating to a “hold” rating in a report on Friday, November 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $42.44.
In other Omnicell news, EVP Dan S. Johnston sold 8,850 shares of the business’s stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $33.65, for a total transaction of $297,802.50. Following the completion of the transaction, the executive vice president now owns 58,877 shares of the company’s stock, valued at $1,981,211.05. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP J Christopher Drew sold 20,000 shares of the business’s stock in a transaction dated Tuesday, November 8th. The stock was sold at an average price of $31.95, for a total value of $639,000.00. Following the transaction, the vice president now directly owns 139,844 shares of the company’s stock, valued at approximately $4,468,015.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,918 shares of company stock valued at $1,006,411. Insiders own 3.75% of the company’s stock.
Omnicell Company Profile
Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).